Asthma. Asthma
Conditions
Interventions
Intervention 1: Intervention group: 44 adults with asthma received one 200 microgram selenium supplement tablet and one 400 international unit (IU) vitamin E capsule daily for 8 weeks. Intervention 2:
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Asthma diagnosis based on the criteria of the American Lung Association (ALA) and confirmed by a pulmonologist FEV<80% Age 18 to 70 years Use of at least one dose of inhaled steroid per day Willingness to cooperate and written consent of the individual Person's ability to carry out and complete the study and cooperate with the researcher Not taking supplements of vitamin E, selenium and other antioxidants (omega 3, choline, vitamin C, etc.) during the last 6 weeks
Exclusion criteria
Exclusion criteria: Pregnants or expect to be pregnant during the study, and nursing mothers Respiratory infection in the last 6 weeks Patients with COPD, severe liver disease (NAFLD with grade 3 and above and cirrhosis), kidney disease and various cancers Users of immunosuppressive drugs, antioxidants and non-steroidal anti-inflammatory drugs (NSAIDS) Unwillingness to continue cooperation Migration and unavailability of people Creating a side effect or any abnormal reaction in the patient due to taking a supplement or placebo Death of people Poor cooperation, low adherence and non-acceptance of supplements (less than 80%) Changes in the amount and type of treatment, medication, physical activity and diet during the study period The urgency of withdrawing people from the study based on the diagnosis of a specialist doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pulmonary function. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Spirometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammation. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Serum level of interleukin 6.;Antioxidant status. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Serum level of malondialdehyde (MDA) and total antioxidant capacity (TAC).;Disease control. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: ACT asthma control questionnaire.;Quality of life. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: SF-36 questionnaire.;Quality of sleep. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: STOP BANG questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Reza Vafa
Iran University of Medical Sciences
Outcome results
None listed